Advanced search
Publication Cover
Journal of Chemotherapy Volume 36, 2024 - Issue 1
Submit an article Journal homepage
69
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA2

Yali Rena Department of Pharmacy, Nantong Health College of Jiangsu Province, Nantong, Jiangsu, ChinaView further author information
,
Qianqian Jub Department of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, ChinaView further author information
,
Jinlin Zhangc Department of Pharmacy, Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu, ChinaView further author information
,
Wei Gua Department of Pharmacy, Nantong Health College of Jiangsu Province, Nantong, Jiangsu, ChinaView further author information
&
Jin Dud Department of Cardiothoracic Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;e Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
Pages 72-81 | Received 08 Jul 2022, Accepted 22 Apr 2023, Published online: 17 May 2023

References

  • Demarest CT, Chang AC. The landmark series: multimodal therapy for esophageal cancer. Ann Surg Oncol. 2021;28(6):3375–3382.
  • He Z, Ke Y. Precision screening for esophageal squamous cell carcinoma in China. Chin J Cancer Res. 2020;32(6):673–682.
  • Ma Z, Yuan M, Bao Y, et al. Survival of neoadjuvant and adjuvant therapy compared with surgery alone for resectable esophageal squamous cell carcinoma: a systemic review and network Meta-Analysis. Front Oncol. 2021;11:728185.
  • Koyanagi K, Kanamori K, Ninomiya Y, et al. Progress in multimodal treatment for advanced esophageal squamous cell carcinoma: results of Multi-Institutional trials conducted in Japan. Cancers. 2020;13(1):51.
  • Holakouie-Naieni K, Mansournia MA, Doosti-Irani A, et al. Treatment-related complications in patients with esophageal cancer: a systematic review and network meta-analysis. Surgeon. 2021;19(1):37–48.
  • Taheri M, Shoorei H, Tondro Anamag F, et al. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. Exp Mol Pathol. 2021;123:104602.
  • Ashrafizadeh M, Hushmandi K, Hashemi M, et al. Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancer. Biomolecules. 2020;10(8):1159.
  • Ashrafizadeh M, Zarrabi A, Hashemipour M, et al. Sensing the scent of death: modulation of microRNAs by curcumin in gastrointestinal cancers. Pharmacol Res. 2020;160:105199.
  • Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: role of microRNAs and upstream mediators. Cell Signal. 2021;78:109871.
  • Pockar S, Globocnik Petrovic M, Peterlin B, et al. MiRNA as biomarker for uveitis - A systematic review of the literature. Gene. 2019;696:162–175.
  • Sang C, Chao C, Wang M, et al. Identification and validation of hub microRNAs dysregulated in esophageal squamous cell carcinoma. Aging (Albany NY). 2020;12(10):9807–9824.
  • Meng WJ, Pathak S, Zhang X, et al. Expressions of miR-302a, miR-105, and miR-888 play critical roles in pathogenesis, radiotherapy, and prognosis on rectal cancer patients: a study from rectal cancer patients in a Swedish rectal cancer trial of preoperative radiotherapy to big database analyses. Front Oncol. 2020;10:567042.
  • Liu J, Wang Y, Ji P, et al. Application of the microRNA-302/367 cluster in cancer therapy. Cancer Sci. 2020;111(4):1065–1075.
  • Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40(14):2483–2495.
  • Zhao P, Jiang D, Huang Y, et al. EphA2: a promising therapeutic target in breast cancer. J Genet Genomics. 2021;48(4):261–267.
  • London M, Gallo E. The EphA2 and cancer connection: potential for immune-based interventions. Mol Biol Rep. 2020;47(10):8037–8048.
  • Salem AF, Gambini L, Billet S, et al. Prostate cancer metastases are strongly inhibited by agonistic Epha2 ligands in an orthotopic mouse model. Cancers. 2020;12(10):2854.
  • Shi H, Yu F, Mao Y, et al. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. J Thorac Dis. 2018 May;10(5):2779–2788.
  • Han X, Zhu Y, Shen L, et al. PTIP inhibits cell invasion in esophageal squamous cell carcinoma via modulation of EphA2 expression. Front Oncol. 2021;11:629916.
  • Du J, He Y, Wu W, et al. Targeting EphA2 with miR-124 mediates erlotinib resistance in K-RAS mutated pancreatic cancer. J Pharm Pharmacol. 2019;71(2):196–205.
  • Wei D, Ke YQ, Duan P, et al. MicroRNA-302a-3p induces ferroptosis of non-small cell lung cancer cells via targeting ferroportin. Free Radic Res. 2021;55(7):821–830.
  • Shi H, Mao Y, Ju Q, et al. C-terminal binding protein2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis. Int J Oncol. 2018;53(1):167–176.
  • Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12–20.
  • Xiao Y, Lin FT, Lin WC. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. Proc Natl Acad Sci USA. 2021;118(3):1–12.
  • Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36.
  • Jiang L, Park MJ, Cho CJ, et al. ADAR1 suppresses interferon signaling in gastric cancer cells by MicroRNA-302a-Mediated IRF9/STAT1 regulation. IJMS. 2020;21(17):6195.
  • Xiao T, Xiao Y, Wang W, et al. Targeting EphA2 in cancer. J Hematol Oncol. 2020;13(1):114.
  • Wu Y, Huang J, Ivan C, et al. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021;163(1):181–190.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.